Psychedelic Science 2025 – the Fifth and Largest Psychedelic Conference in History – Announced for June 16-20 2025 in Denver, Colorado
February 13, 2024 13:29 ET
|
Multidisciplinary Association for Psychedelic Studies (MAPS)
SAN JOSE, Calif. , Feb. 13, 2024 (GLOBE NEWSWIRE) -- The Multidisciplinary Association for Psychedelic Studies (MAPS) has announced that the Psychedelic Science 2025 Conference will convene in the...
Optimi Health Secures Amendment to Increase Quantities Of MDMA, MDA, And 2C-B Under Controlled Drugs And Substances Dealer’s Licence
January 19, 2024 07:30 ET
|
Optimi Health Corp.
Optimi Health granted amendment to its Health Canada Controlled Drugs and Substances Licence.
MAPS Unveils Improved Fiscal Sponsorship Program, Empowering Innovators in the Psychedelic Movement
January 16, 2024 16:27 ET
|
Multidisciplinary Association for Psychedelic Studies (MAPS)
To date, MAPS has supported nearly 70 organizations worldwide to advance charitable projects in the psychedelic movementCurrently, MAPS serves as a fiscal sponsor for 10 organizations in the newly...
HERE and Murata Manufacturing join forces to tackle traffic woes in Jakarta, Indonesia
December 05, 2023 20:00 ET
|
HERE Technologies
HERE map and traffic data are integrated with Murata’s traffic counter system to help city authorities in Indonesia’s capital city Jakarta to improve traffic management ...
Optimi Health Achieves Genetics Milestone and Completes Psilocybin Extract Validation and Stability Testing
November 28, 2023 07:42 ET
|
Optimi Health Corp.
VANCOUVER, British Columbia, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a leading end-to-end drug researcher and formulator licensed by Health...
Optimi Health Announces Third and Final Tranche of CAD $1,000,000 Secured for Debt Financing
November 02, 2023 07:30 ET
|
Optimi Health Corp.
VANCOUVER, British Columbia, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi Health” or the “Company”), a Canadian drug research and formulation...
Optimi Health Celebrates Encouraging Results from the MAPS Phase 3 MDMA-Assisted Therapy Clinical Trial
September 14, 2023 14:59 ET
|
Optimi Health Corp.
VANCOUVER, British Columbia, Sept. 14, 2023 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a Canadian psychedelics drug research and formulation company, is pleased...
HERE data chosen by majority of automakers for their EU intelligent speed assistance solution
September 05, 2023 03:00 ET
|
HERE Technologies
More than 50 brands from 21 global automakers select the HERE ISA Map to comply with the EU Intelligent Speed Assistance regulation. HERE location data and software used in 180 million vehicles...
MAPS Launches Online Video Sessions from Psychedelic Science 2023 with The Virtual Trip
August 30, 2023 16:41 ET
|
Multidisciplinary Association for Psychedelic Studies (MAPS)
PS2023: The Virtual Trip offers an opportunity to access a wide spectrum of sessions from Psychedelic Science 2023, the largest psychedelics conference in history.With a rolling release schedule,...
Optimi Health Announces CAD $3,000,000 Senior Debt Financing
August 10, 2023 07:30 ET
|
Optimi Health Corp.
VANCOUVER, British Columbia, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a Canadian drug research and formulation company licensed by Health Canada...